You mean "any chance of succeeding" as in U.S. Treatment of Acute COVID right? Because with our Brazil trial design of IV Dosing for 4 weeks we have significant potential of success, along with 1:1 trial arms and larger "N" of 306.
But yes, it is sad that trial design was so awful. The fact that the drug proved successful but because of the trial design we failed, makes me more bitter I would say.
Hoping for some success in Longhauler Trial, but once again we have too small of a trial size, making it infinitely more difficult to obtain proper signals for a P3 LH
Market Data 
Markets 
AI
